Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Opus Genetics (IRD) launched a primary offering of 3,827,751 shares of common stock and 7,177,033 pre‑funded warrants at $2.09 and $2.0899, respectively, for gross proceeds of approximately $23.0 million, before ~$0.3 million of expenses. The pre‑funded warrants are immediately exercisable at $0.0001 per share and this prospectus also covers 7,177,033 shares issuable upon their exercise. There is no underwriter or placement agent.
The company estimates net proceeds of about $22.7 million, assuming full warrant exercise, to advance its LCA5 and BEST1 gene therapy programs and for working capital and general corporate purposes. Shares outstanding were 65,002,665 as of October 31, 2025; the company states 76,007,449 would be outstanding assuming full exercise of the pre‑funded warrants.
Recent updates note constructive FDA RMAT feedback on OPGx‑LCA5 and a planned Phase 3 design, with dosing anticipated in the second half of 2026 and topline data about a year later. Including expected proceeds, management projects cash resources funding operations into the second half of 2027.
Opus Genetics, Inc. (IRD) reported an insider transaction amendment. The Chief Executive Officer and Director filed a Form 4/A clarifying that 30,350 shares of common stock were withheld by the issuer on 11/01/2025 to satisfy tax obligations from an RSU vesting event, coded F (tax withholding). This was not an open‑market sale.
Following the transaction, the reporting person beneficially owned 1,291,654 shares directly. The amendment was filed solely to add a footnote explaining the nature of the transaction.
Opus Genetics (IRD) disclosed an insider transaction by its Chief Executive Officer and Director. On 11/01/2025, a Form 4 reports a transaction coded “F” involving 30,350 shares of common stock at $2.30 per share. After this transaction, the reporting person beneficially owned 1,291,654 shares, held directly.
Opus Genetics (IRD) reported an insider transaction on a Form 4. On 10/22/2025, a transaction in Common Stock with code F involved 23,795 shares at $1.95. After this activity, the reporting person beneficially owns 319,005 shares, held directly.
The reporting person is listed as a Director and Officer (President), and the filing was made by one reporting person.
Opus Genetics reported encouraging early results from its Phase 1/2 OPGx-LCA5-1001 trial of OPGx-LCA5, a gene therapy for Leber congenital amaurosis type 5. The treatment has been well tolerated in all six participants (three adults and three pediatric), with no ocular serious adverse events or dose-limiting toxicities and only mild, expected eye-related side effects not attributed to the study drug.
All three pediatric participants with severe baseline vision impairment showed improvements across several vision measures after a single subretinal injection, including an average 0.3 logMAR gain in visual acuity and more than a 1 log unit increase in cone sensitivity to red and blue light, alongside mobility and microperimetry benefits. In adults, improvements in visual acuity were sustained through 18 months. The company plans to meet with the U.S. Food and Drug Administration in the fourth quarter of 2025 to discuss these results and potential next steps for the program.
Opus Genetics, Inc. filed a Form S-8 on September 26, 2025 to register securities under its 2020 Equity Incentive Plan. The filing incorporates by reference the company’s 2024 Annual Report (filed March 31, 2025), subsequent quarterly reports (filed May 15, 2025 and August 13, 2025) and multiple current reports filed between January 7, 2025 and September 2, 2025. The Registration Statement relies on prior effective S-8 registrations and includes customary exhibits and a power of attorney signed by management and directors.